Literature DB >> 20397273

Cystic fibrosis and Crohn's disease: successful treatment and long term remission with infliximab.

Francesca Vincenzi1, Barbara Bizzarri, Alessia Ghiselli, Nicola de' Angelis, Fabiola Fornaroli, Gian Luigi de' Angelis.   

Abstract

The association of cystic fibrosis and Crohn's disease (CD) is well known, but to date, there are very few cases in the literature of patients suffering from mucoviscidosis who have required treatment with infliximab. We report the case of a 23-year-old patient suffering from cystic fibrosis and severe CD treated successfully with infliximab without any infective complications or worsening of the pulmonary disease and with a long term (2 years) complete remission.

Entities:  

Keywords:  Crohn’s disease; Cystic fibrosis; Infliximab

Mesh：

Substances：

Year:  2010        PMID： 20397273      PMCID： PMC2856836          DOI： 10.3748/wjg.v16.i15.1924

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  30 in total

1.  Immunomodulatory therapy for pediatric inflammatory bowel disease: changing patterns of use, 1990-2000.

Authors:  James Markowitz; Kathy Grancher; Nina Kohn; Fredric Daum
Journal:  Am J Gastroenterol       Date:  2002-04       Impact factor: 10.864

2.  Use of infliximab in the treatment of Crohn's disease in children and adolescents.

Authors:  J S Hyams; J Markowitz; R Wyllie
Journal:  J Pediatr       Date:  2000-08       Impact factor: 4.406

3.  Research agenda for pediatric gastroenterology, hepatology and nutrition: cystic fibrosis and pancreatic diseases. Report of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition for the Children's Digestive Health and Nutrition Foundation.

Authors:  Mark E Lowe; Nadia Ameen; Stephen Freedman; Andrew E Mulberg; Steven L Werlin
Journal:  J Pediatr Gastroenterol Nutr       Date:  2002       Impact factor: 2.839

4.  Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.

Authors:  Stephen B Hanauer; Carrie L Wagner; Mohan Bala; Lloyd Mayer; Suzanne Travers; Robert H Diamond; Allan Olson; Warren Bao; Paul Rutgeerts
Journal:  Clin Gastroenterol Hepatol       Date:  2004-07       Impact factor: 11.382

5.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Authors:  Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

6.  Gastrointestinal, liver, and pancreatic involvement in adult patients with cystic fibrosis.

Authors:  I Modolell; A Alvarez; L Guarner; J De Gracia; J R Malagelada
Journal:  Pancreas       Date:  2001-05       Impact factor: 3.327

7.  Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease.

Authors:  Robert Baldassano; Christian P Braegger; Johanna C Escher; Kimberly DeWoody; David F Hendricks; Gregory F Keenan; Harland S Winter
Journal:  Am J Gastroenterol       Date:  2003-04       Impact factor: 10.864

8.  Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.

Authors:  O Borrelli; C Bascietto; F Viola; M Bueno de Mesquita; M Barbato; V Mancini; S Bosco; S Cucchiara
Journal:  Dig Liver Dis       Date:  2004-05       Impact factor: 4.088

9.  Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab.

Authors:  Erasmo Miele; Jonathan E Markowitz; Petar Mamula; Robert N Baldassano
Journal:  J Pediatr Gastroenterol Nutr       Date:  2004-05       Impact factor: 2.839

10.  Infliximab maintenance therapy for fistulizing Crohn's disease.

Authors:  Bruce E Sands; Frank H Anderson; Charles N Bernstein; William Y Chey; Brian G Feagan; Richard N Fedorak; Michael A Kamm; Joshua R Korzenik; Bret A Lashner; Jane E Onken; Daniel Rachmilewitz; Paul Rutgeerts; Gary Wild; Douglas C Wolf; Paul A Marsters; Suzanne B Travers; Marion A Blank; Sander J van Deventer
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245
View more
  3 in total

1.  Improvements in cystic fibrosis lung disease and airway inflammation associated with etanercept therapy for rheumatoid arthritis: a case report.

Authors:  S Visser; M Martin; D J Serisier
Journal:  Lung       Date:  2012-06-04       Impact factor: 2.584

2.  Disrupted tight junctions in the small intestine of cystic fibrosis mice.

Authors:  Robert C De Lisle
Journal:  Cell Tissue Res       Date:  2013-10-30       Impact factor: 5.249

3.  Metastatic bladder cancer presenting with persistent hematuria in young man with cystic fibrosis.

Authors:  Premal Patel; Harvey R Rabin; Michael M Vickers; Michael D Parkins
Journal:  Case Rep Pulmonol       Date:  2013-05-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.